Compare VYGR & USAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYGR | USAU |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.3M | 214.2M |
| IPO Year | 2015 | 2020 |
| Metric | VYGR | USAU |
|---|---|---|
| Price | $3.09 | $14.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $16.50 | ★ $22.83 |
| AVG Volume (30 Days) | ★ 404.5K | 160.8K |
| Earning Date | 05-08-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.11 |
| EPS | N/A | ★ N/A |
| Revenue | $10,135,000.00 | ★ $17,402,000.00 |
| Revenue This Year | $34.04 | N/A |
| Revenue Next Year | $7.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.94 | $12.23 |
| 52 Week High | $5.55 | $23.72 |
| Indicator | VYGR | USAU |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 46.15 |
| Support Level | $2.95 | $14.84 |
| Resistance Level | $3.30 | $16.47 |
| Average True Range (ATR) | 0.14 | 0.61 |
| MACD | -0.03 | -0.15 |
| Stochastic Oscillator | 13.19 | 20.38 |
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
U.S. Gold Corp is a gold, copper and precious metals development and exploration company pursuing exploration opportunities mainly in Wyoming, Nevada and Idaho. It is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada and the Challis Gold Project in Idaho. The company is engaged in the exploration and evaluation of its mineral properties, which is the single operating segment.